Lecanemab vs aducanumab: mechanism and ARIA rates

The Amyloid Hypothesis and Why Target Selectivity Matters

Alzheimer's disease is characterised by the progressive accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles, and the amyloid hypothesis holds that Aβ aggregation is a primary driver of neurodegeneration. Both lecanemab and aducanumab are humanized IgG1 monoclonal antibodies designed to clear pathological Aβ species — but the specific Aβ forms each antibody targets differ substantially, and those differences have profound consequences for efficacy and safety. According to the FDA, lecanemab received approval in January 2023 and aducanumab in June 2021, making them consecutive milestones in disease-modifying Alzheimer's therapy.

Not all Aβ aggregates are equally toxic. Aβ exists along a spectrum from soluble monomers through intermediate protofibrillar species to insoluble fibrillar plaques. Research has established that soluble protofibrils — large oligomeric assemblies 30–100 nm in length — disrupt memory-related electrophysiological systems and are considered the most neurotoxic Aβ species. The therapeutic logic of each antibody flows directly from which point on this spectrum it engages most strongly.

How Lecanemab Targets Soluble Protofibrils

Lecanemab works by selectively binding soluble Aβ protofibrils with high nanomolar affinity, facilitating their removal by microglia before they can consolidate into irreversible fibrillar plaques. This protofibril-selective mechanism is the defining feature of lecanemab's pharmacology and the primary reason it differs from earlier anti-amyloid antibodies.

Binding Affinity and Kinetics

Surface plasmon resonance studies have characterised lecanemab's binding hierarchy with precision. For small protofibrils, the equilibrium dissociation constant (Kd) is 2.2 ± 1.0 nM, with a very fast association rate of 2.5 ± 0.53 × 10⁷ M⁻¹s⁻¹. For large protofibrils, binding is even tighter: Kd = 0.79 ± 0.10 nM with an association rate of 3.8 ± 0.56 × 10⁷ M⁻¹s⁻¹. By contrast, lecanemab binds monomers only weakly (Kd = 7,300 ± 990 nM) and shows no significant binding to oligomers. Crucially, its affinity for insoluble fibrils is tenfold weaker than for protofibrils.

Clearance and Contact System Inhibition

Once bound to protofibrils, lecanemab facilitates Fc receptor-mediated phagocytosis by microglia, promoting removal of toxic species before they convert into insoluble plaques. Beyond direct clearance, recent research has revealed an additional mechanistic dimension: Aβ protofibrils preferentially activate the plasma contact system, promoting coagulation and neuroinflammation. Lecanemab blocks this activation by preventing the binding of coagulation factor XII (FXII) and high molecular weight kininogen (HK) to Aβ protofibrils — providing a molecular explanation for why protofibril-selective targeting may be therapeutically superior.

"Lecanemab's tenfold stronger binding to soluble Aβ protofibrils compared to insoluble fibrils represents a paradigm shift in anti-amyloid therapy, targeting the most toxic Aβ species before they form irreversible plaques."

How Aducanumab Targets Fibrillar Aggregates

Aducanumab targets a broader range of Aβ aggregates than lecanemab, with a preference for mature insoluble fibrils and plaques, while also binding soluble oligomers. This wider binding profile reflects a different therapeutic strategy: removing established fibrillar pathology rather than intercepting soluble intermediates.

Binding Profile and Aggregation Kinetics

In direct comparative analyses using inhibition ELISA, immunodepletion, and surface plasmon resonance, aducanumab demonstrated strong preferential binding to fibrils, moderate binding to protofibrils (tenfold weaker than lecanemab), binding to soluble oligomers, and weak binding to monomers. Aducanumab disrupts amyloid aggregation kinetics through a multistep process affecting both primary nucleation from monomeric protein and secondary nucleation on existing fibrils. The antibody binds fibrils and targets them for microglial-mediated removal.

Dose-Dependent Kinetics and Half-Life

Aducanumab is administered intravenously at 10 mg/kg every four weeks (after a titration period) and demonstrates dose- and time-dependent reduction in brain Aβ plaques. Its long half-life means that maximal clinical benefit emerges around five months after treatment initiation as steady-state concentrations build. Aducanumab dose-dependently increases plasma mid-domain tau and lowers CSF p-tau181, p-tau217, and t-tau levels — biomarker changes consistent with downstream neurodegeneration suppression. In the TRAILBLAZER-ALZ 4 trial comparing donanemab with aducanumab, aducanumab showed only 1.6% amyloid plaque clearance compared to 37.9% for donanemab, highlighting the relative limitations of aducanumab's plaque-clearing efficacy.

Clinical Efficacy and ARIA Safety Profiles Compared

The mechanistic differences between lecanemab and aducanumab translate directly into measurable differences in clinical trial outcomes. Lecanemab's Phase 3 CLARITY AD trial and aducanumab's EMERGE trial provide the most robust head-to-head comparison available from published data, according to registries maintained by the NIH.

CLARITY AD: Lecanemab Phase 3 Results

In the CLARITY AD trial, lecanemab achieved its primary endpoint: a 27% reduction in cognitive decline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale compared to placebo, representing a difference of -0.45 points (p<0.001) at 18 months. All key secondary endpoints — including ADAS-cog14, ADCOMS, and ADCS-MCI-ADL — showed statistically significant improvements. Amyloid clearance was substantial: 68% of treated individuals achieved complete amyloid clearance by 18 months. The most common adverse reactions were infusion-related reactions (26%), falls (11%), and headache (11%). Real-world data shows a 16.9% ARIA detection rate, with higher CSF p-tau181 levels predicting ARIA occurrence.

EMERGE: Aducanumab Phase 3 Results

In the EMERGE trial's high-dose group (10 mg/kg), aducanumab achieved a 22% reduction in cognitive decline, with a CDR-SB difference of -0.39 versus placebo (95% CI: -0.69 to -0.09; p=0.012). Aducanumab's ARIA-E incidence was 35%, with ARIA-H at 19.1% — significantly higher than lecanemab's rates. In the TRAILBLAZER-ALZ 4 trial, aducanumab showed only 1.6% amyloid plaque clearance compared to 37.9% for donanemab, raising questions about its relative plaque-clearing capacity. The main risk factors for ARIA with aducanumab are antibody dose and presence of the ApoE4 allele.

Why Does Aducanumab Cause More ARIA?

The mechanistic explanation for the ARIA differential lies in vascular amyloid binding. Aducanumab's stronger affinity for mature fibrillar aggregates, including vascular amyloid associated with cerebral amyloid angiopathy (CAA), is believed to cause greater vascular disruption. Lecanemab's selectivity for parenchymal protofibrils rather than vascular amyloid may explain its improved safety profile — a distinction consistent with its tenfold preference for soluble protofibrils over fibrillar structures. As documented by the EMA in its regulatory reviews, ARIA monitoring is a central element of risk management for this drug class.

Patient Selection, Biomarkers, and Treatment Strategy

Both antibodies require confirmation of amyloid pathology via amyloid PET or CSF biomarkers before treatment initiation, but the optimal patient profiles differ in ways that reflect each drug's mechanism. Understanding these distinctions is essential for precision medicine approaches in early Alzheimer's disease, a priority area for the WHO's global dementia action plan.

Optimal Candidates for Lecanemab

Lecanemab is indicated for early Alzheimer's disease — specifically MCI or mild dementia — and shows particular efficacy in patients with low CSF p-tau181 levels (below 78.6 pg/ml). This suggests that patients in earlier stages of tau accumulation may derive greater benefit, consistent with the hypothesis that intercepting protofibrils before widespread tau pathology is established yields the greatest clinical gain. Lecanemab carries higher risk in patients with ApoE4 homozygosity, and this genetic factor should inform treatment decisions. A subcutaneous maintenance formulation (500 mg weekly) has demonstrated bioequivalence with intravenous dosing, showing a 104% exposure ratio — a development that may improve long-term treatment convenience.

Optimal Candidates for Aducanumab

Aducanumab is indicated for early Alzheimer's disease with confirmed amyloid pathology. ApoE4 carriers face higher ARIA risk and require more intensive imaging surveillance. Aducanumab's longer dosing interval (every four weeks versus every two weeks for lecanemab) may offer a practical advantage for some patients, though its requirement for approximately five months to reach therapeutic steady state necessitates extended commitment before clinical benefit becomes apparent.

Biomarker-Guided Therapy

Both antibodies show biomarker changes consistent with downstream neurodegeneration suppression — reductions in CSF p-tau181, p-tau217, and t-tau. However, lecanemab's particular efficacy in patients with absent or low tau accumulation suggests that CSF p-tau181 and p-tau217 levels could serve as predictive biomarkers for therapeutic response, enabling more refined patient stratification. This biomarker-guided approach aligns with the broader trajectory of precision oncology and neurology, where treatment selection is increasingly driven by molecular characterisation rather than clinical stage alone. PatSnap's life sciences intelligence platform enables researchers to map these biomarker-patent intersections across the Alzheimer's pipeline.